Sonia Leadmon

Intermediate-Dose versus Low-Dose Cyclophosphamide and Granulocyte Colony-Stimulating Factor for Peripheral Blood Stem Cell Mobilization in Patients with Multiple Myeloma Treated with Novel Induction Therapies

Mehdi Hamadani, Samith T. Kochuparambil, Salman Osman et al. · Biology of Blood and Marrow Transplantation · 2012 · 72 citations · Full text

Medicine, Hematology, Pharmacotherapy +15

Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies

Farrukh T. Awan, Samith T. Kochuparambil, Debbie Falconer et al. · Bone Marrow Transplantation · 2013 · 49 citations

Medicine, Oncology, Pharmacology +16

Hematopoietic progenitor cell mobilization with “just-in-time” plerixafor approach is a cost-effective alternative to routine plerixafor use

Lauren Veltri, Aaron Cumpston, Alexandra Shillingburg et al. · Cytotherapy · 2015 · 33 citations · Full text

Medicine, Cell Biology, Hematology +16

Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy‐era with plerixafor and G‐CSF has superior efficacy but significantly higher costs compared to mobilization with low‐dose cyclophosphamide and G‐CSF

Lubna N. Chaudhary, Farrukh T. Awan, Aaron Cumpston et al. · Journal of Clinical Apheresis · 2013 · 32 citations

Medicine, Pharmacoeconomics, Pharmacotherapy +16

Predictors and Impact of Thirty-Day Readmission on Patient Outcomes and Health Care Costs after Reduced-Toxicity Conditioning Allogeneic Hematopoietic Cell Transplantation

Sherri Rauenzahn, Quoc Truong, Aaron Cumpston et al. · Biology of Blood and Marrow Transplantation · 2013 · 18 citations · Full text

Medicine, Hematology, Pharmacoeconomics +16